Friday to Sunday, February 28 – March 2, 2025

Topics and schedule are subject to change. Times indicated are eastern time.

Friday, February 28, 2025

6:30 PM – 7:00 PM — Registration and Welcome Reception

7:00 PM – 9:00 PM — Keynote Session: Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC)

CDK4/6 Inhibitors for HR-Positive mBC

• Long-term follow-up from pivotal clinical trials of abemaciclib, palbociclib and ribociclib for premenopausaland postmenopausal patients with HR-positive, HER2-negative mBC
• Key findings from and implications of other recently reported studies, such as RIGHT Choice, exploring the efficacy of up-front CDK4/6 inhibitor-based treatment for HR-positive, HER2-negative mBC
• Spectrum, frequency and severity of clinically relevant toxicities documented with abemaciclib, palbociclib and ribociclib
• Optimal selection of a CDK4/6 inhibitor and an endocrine partner for HR-positive, HER2-negative mBC; implications of poor-risk features, patient comorbidities and prior therapeutic exposure
• Key findings from the Phase III postMONARCH study evaluating abemaciclib with fulvestrant for patients with HR-positive, HER2-negative mBC and disease progression on a CDK4/6 inhibitor and endocrine therapy

Targeting the PTEN/PI3K/AKT Pathway in HR-Positive mBC

• Incidence of genomic alterations in the PTEN/PI3K/AKT pathway in patients with HR-positive mBC; optimal timing and approach to testing
• Key data, including emerging overall survival findings, from the Phase III INAVO120 trial assessing inavolisib with palbociclib/fulvestrant as first-line therapy for patients with PIK3CA-mutated, HR-positive, HER2-negative mBC whose disease had progressed during or within 12 months of completing adjuvant endocrine therapy
• Recent FDA approval of inavolisib/palbociclib/fulvestrant and current clinical role
• Key efficacy and safety data from the Phase III CAPItello-291 study evaluating capivasertib/fulvestrant for HR-positive, HER2-negative mBC progressing on endocrine therapy with or without a CDK4/6 inhibitor
• Role of capivasertib opposite other evidence-based options for previously treated HR-positive, HER2-negative mBC
• Long-term data with alpelisib-based treatment for patients with progressive HR-positive mBC with a PIK3CA mutation; optimal use in clinical practice

Role of Oral Selective Estrogen Receptor Degraders (SERDs) in the Management of HR-Positive mBC

• Incidence of ESR1 mutations in HR-positive, HER2-negative mBC; optimal approach to assessment
• Published results from the Phase III EMERALD trial of elacestrant for pretreated HR-positive, HER2-negative mBC; outcomes for patients with and without ESR1 mutations
• FDA approval of elacestrant for HR-positive, HER2-negative, ESR1-mutated mBC; optimal incorporation into clinical management algorithms
• Recently presented results of the Phase III EMBER-3 study of imlunestrant alone or in combination with abemaciclib for HR-positive, HER2-negative mBC pretreated with endocrine therapy with or without a CDK4/6 inhibitor
• Available findings with and ongoing evaluation of other oral SERDs alone and in combination with other systemic therapies for advanced HR-positive, HER2-negative breast cancer

Antibody-Drug Conjugates for HR-Positive mBC

• Long-term follow-up data from the Phase III DESTINY-Breast04 study evaluating trastuzumab deruxtecan (T-DXd) versus chemotherapy for patients with previously treated HER2-low advanced breast cancer
• Published results from the Phase III DESTINY-Breast06 trial of T-DXd for patients with HR-positive, HER2-low and HER2-ultralow mBC previously treated with endocrine therapy
• Appropriate sequencing of T-DXd opposite other standard therapies for previously treated HR-positive, HER2-low and HER2-ultralow advanced breast cancer
• Major findings from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan for HR-positive, HER2-negative mBC
• Recently published efficacy and safety findings from the Phase III TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy for pretreated HR-positive, HER2-negative mBC; recent FDA approval and current clinical role
• Rationale for targeting HER3 in mBC; early findings with and ongoing investigation of patritumab deruxtecan for HR-positive mBC

Saturday, March 1, 2025  

6:45 AM – 7:45 AM — Registration and Breakfast

7:45 AM – 9:25 AM — Module 1: HER2-Positive, Triple-Negative and Localized Breast Cancer

HER2-Positive Breast Cancer

• Selection of an appropriate neoadjuvant or adjuvant regimen for patients with HER2-positive localized breast cancer
• Clinical factors guiding the use of neratinib as extended adjuvant therapy for HER2-positive localized breast cancer; identification of appropriate candidates for treatment with this agent
• Dose escalation and other available approaches to mitigate neratinib-associated gastrointestinal toxicities
• Published findings from key studies establishing the efficacy of T-DXd and tucatinib-based therapy for patients with HER2-positive mBC
• Incidence of brain metastases in HER2-positive mBC; available data documenting the central nervous system (CNS) activity of T-DXd and tucatinib-based therapy
• Optimal integration of T-DXd and tucatinib-based therapy into the management of HER2-positive mBC with and without CNS involvement
• Long-term findings with other HER2-targeted approaches, such as neratinib/capecitabine, for patients with progressive HER2-positive mBC

Triple-Negative Breast Cancer (TNBC)

• Long-term data, including final overall survival results, from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
• Patient selection for and practical application of neoadjuvant and adjuvant pembrolizumab
• Key findings with and clinical role of adjuvant olaparib for patients with localized HER2-negative breast cancer and a germline BRCA1/2 mutation
• Extended follow-up with pembrolizumab/chemotherapy for previously untreated PD-L1-positive metastatic TNBC (mTNBC)
• Published research comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory (R/R) mTNBC; current role and optimal sequencing
• Available data with and ongoing evaluation of Dato-DXd alone or in combination with an immune checkpoint inhibitor for mTNBC
• Key findings from the DESTINY-Breast04 trial of T-DXd for previously treated HER2-low mBC; optimal sequencing of this strategy for HR-negative disease
• Other promising novel agents and strategies under investigation for patients with mTNBC

Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer

• Factors affecting the decision to consult a genomic assay for HR-positive, HER2-negative localized breast cancer
• Key studies informing the use of the 21-gene Recurrence Score^® (RS) to guide neoadjuvant and adjuvant treatment decision-making; practical interpretation of 21-gene RS results
• Clinical trial database informing the use of extended adjuvant endocrine therapy for patients with HR-positive breast cancer
• Available datasets evaluating the utility of the Breast Cancer Index® to inform the use of extended adjuvant endocrine therapy for patients with HR-positive localized breast cancer; integration into treatment decision-making
• Clinical role and optimal timing of initiation/duration for ovarian function suppression (OFS) as a component of adjuvant endocrine therapy for premenopausal patients with HR-positive breast cancer
• Utility of OFS to preserve fertility and/or prevent premature chemotherapy-induced ovarian insufficiency in premenopausal patients with breast cancer

Current Role of CDK4/6 Inhibitors in the Localized Setting

• Extended follow-up from the Phase III monarchE trial evaluating the addition of abemaciclib to adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Key findings with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the Phase III NATALEE trial
• FDA-approved indications for adjuvant abemaciclib and ribociclib and identification of appropriate candidates for their use
• Data exploring the effect of abemaciclib or ribociclib dose reductions on efficacy in patients with HR-positive, HER2-negative localized breast cancer
• Early data with CDK4/6 inhibitors as neoadjuvant therapy for localized HR-positive breast cancer
• Ongoing Phase III trials evaluating oral SERDs in combination with CDK4/6 inhibitors in the adjuvant setting

9:25 AM – 9:45 AM — Morning Break

9:45 AM – 10:35 AM — Module 2: Neuroendocrine Tumors (NETs)

Initial Therapy for Advanced NETs

• Patient- and disease-related factors affecting the selection of first-line systemic treatment for unresectable or metastatic NETs
• Clinical trial database supporting the use of the somatostatin analogs (SSAs) octreotide and lanreotide for patients with advanced NETs
• Effect of tolerability profiles, modes of administration and dosing strategies on selection of SSA therapy
• Recently presented findings from the Phase III STARTER-NET study evaluating first-line combination therapy with everolimus and lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic NETs
• Mechanism of antitumor activity of the peptide receptor radionuclide therapy lutetium Lu 177 dotatate
• Key efficacy and safety findings from the Phase III NETTER-2 trial evaluating lutetium Lu 177 dotatate with octreotide versus high-dose octreotide alone for patients with previously untreated somatostatin receptor-positive advanced NETs

Management of Progressive Advanced NETs

• Long-term outcomes from the Phase III NETTER-1 trial comparing lutetium Lu 177 dotatate and octreotide to high-dose octreotide for advanced midgut NETs progressing on first-line SSA therapy
• Historical data with multitargeted tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, axitinib and lenvatinib, for patients with progressive advanced NETs
• Final results from the Phase III CABINET study evaluating cabozantinib for patients with progressive advanced NETs; clinical activity documented with cabozantinib in the cohort of patients with pancreatic and extrapancreatic NETs
• FDA acceptance of a supplemental new drug application for cabozantinib for previously treated moderately or well-differentiated advanced NETs; potential clinical role
• Rationale for combining multitargeted TKIs with immune checkpoint inhibitors for NETs; ongoing evaluation of these combination approaches
• Other novel agents and strategies under investigation for patients with advanced NETs

10:35 AM – 11:25 AM — Module 3: Chronic Lymphocytic Leukemia (CLL)

Current Role of Covalent Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in Managing CLL

• Clinical, biological (eg, IGHV mutation, del[17p], TP53 mutation) and practical factors in the selection of first-line treatment for patients with CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in clinical decision-making
• Antitumor activity of BTK inhibitors alone versus in combination with anti-CD20 antibodies in the up-front setting; implications for therapeutic selection
• Spectrum, frequency and severity of cardiovascular and other adverse events with BTK inhibitors; optimal monitoring and management protocols
• Key efficacy and safety data with venetoclax-based up-front treatment for CLL; identification of appropriate patients for time-limited therapy
• Current role of BTK and Bcl-2 inhibitors for R/R CLL, including after disease progression on these therapies in a prior line of treatment

Novel Agents and Combination Strategies

• Published datasets evaluating ibrutinib/venetoclax with and without anti-CD20 antibodies for newly diagnosed and R/R CLL
• Recently presented findings from the Phase III AMPLIFY trial evaluating fixed-duration acalabrutinib and venetoclax with or without obinutuzumab as first-line therapy
• Available data with zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax and sonrotoclax, with or without an anti-CD20 antibody; efficacy in patients with del(17p)
• Current role, if any, of novel doublet and triplet combinations for patients with CLL; ongoing Phase III studies
• Recently presented findings from the Phase III BRUIN CLL-321 trial evaluating pirtobrutinib versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab (BR) for BTK inhibitor-pretreated CLL
• Current role of pirtobrutinib for R/R CLL; ongoing Phase III trials of pirtobrutinib alone and in combination
• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for patients with R/R CLL
• FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; optimal selection of patients
• Other promising agents and strategies under investigation for CLL

11:25 AM – 12:15 PM — Module 4: Sarcoma and Other Connective Tissue Neoplasms

Sarcoma

• Historical management of advanced soft tissue sarcoma (STS); selection and sequencing of chemotherapeutic and other approved agents
• Rationale for targeting EZH2 in patients with epithelioid sarcoma; published research supporting the use of the EZH2 inhibitor tazemetostat for advanced epithelioid sarcoma
• Ongoing assessment of tazemetostat in combination with doxorubicin for newly diagnosed epithelioid sarcoma; preliminary data from the Phase Ib portion of the EZH-301 trial and anticipated Phase III results
• Key efficacy and safety data leading to the recent FDA approval of the first-in-class T-cell receptor gene therapy afamitresgene autoleucel for pretreated advanced synovial sarcoma with MAGE-A4 expression; practical considerations for clinical practice
• Recently presented results from the pivotal IGNYTE-ESO trial with letetresgene autoleucel for patients with synovial sarcoma or myxoid/round cell liposarcoma who received 2 or more prior lines of therapy; potential clinical role
• Mechanisms of action of, preliminary findings with and ongoing research on other novel agents and strategies for advanced STS

Other Connective Tissue Neoplasms

• Outcomes associated with local treatment strategies and historically employed systemic approaches for desmoid tumors, such as TKIs, chemotherapy, hormonal therapy and anti-inflammatory agents
• Scientific rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors; mechanism of action of nirogacestat
• Major findings from the Phase III DeFi trial evaluating nirogacestat versus placebo for progressive desmoid tumors, including outcomes in the subgroup of patients with poor prognostic features
• FDA approval of nirogacestat for patients with progressing desmoid tumors; optimal selection of candidates for this strategy
• Outcomes associated with surgical intervention and other traditional treatments for tenosynovial giant cell tumor (TGCT)
• Biological rationale for targeting colony-stimulating factor-1 receptor (CSF1R) in patients with TGCT; mechanistic similarities and differences between approved (pexidartinib, vimseltinib) and investigational (pimicotinib) CSF1R inhibitors
• Available efficacy and safety data with pexidartinib for TGCT and appropriate selection of patients for this therapy
• Published findings from the Phase III MOTION study of vimseltinib for TGCT; recent FDA approval and current clinical role
• Emerging positive data from the Phase III MANEUVER study of pimicotinib for patients with unresectable TGCT

12:15 PM – 1:00 PM — Lunch Break

1:00 PM – 1:50 PM — Module 5: EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive NSCLC

• Long-term data, including overall survival outcomes, with adjuvant osimertinib for EGFR-mutated Stage IB to IIIA NSCLC after complete tumor resection
• Published findings from the Phase III LAURA trial documenting the efficacy and tolerability of osimertinib as consolidation therapy after chemoradiation therapy for patients with unresectable Stage III EGFR-mutated NSCLC
• Major efficacy and safety findings from the Phase III FLAURA2 trial of osimertinib combined with chemotherapy versus osimertinib alone as first-line treatment for EGFR-mutated NSCLC
• Extended follow-up, including emerging overall survival findings, from the Phase III MARIPOSA trial of up-front treatment with amivantamab/lazertinib versus osimertinib for metastatic EGFR-mutant NSCLC
• Optimal selection of patients with newly diagnosed EGFR-mutated NSCLC for treatment with osimertinib monotherapy versus osimertinib/chemotherapy versus amivantamab/lazertinib
• Key data from the Phase III MARIPOSA-2 study supporting the recent FDA approval of amivantamab in combination with platinum-based chemotherapy for progressive EGFR-mutated advanced NSCLC; optimal incorporation in current management algorithms
• Efficacy and safety outcomes documented with a subcutaneous formulation of amivantamab in combination with lazertinib for refractory and treatment-naïve EGFR-mutated advanced NSCLC; potential role in clinical practice

Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC

• Mechanism of action of and published efficacy and safety data with the HER3-targeted antibody-drug conjugate patritumab deruxtecan for patients who have experienced disease progression on an EGFR TKI and platinum-based chemotherapy
• Emerging positive findings from the Phase III HERTHENA-Lung02 trial evaluating patritumab deruxtecan versus doublet chemotherapy for advanced EGFR-mutated NSCLC that has progressed on a third-generation EGFR TKI
• Ongoing FDA review and potential clinical role of patritumab deruxtecan
• Recently presented pooled analysis of the efficacy and safety of Dato-DXd in patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials
• FDA breakthrough therapy designation for Dato-DXd for previously treated advanced EGFR-mutated NSCLC; potential role of this strategy
• Spectrum and incidence of common and more serious treatment-emergent adverse events with patritumab deruxtecan and Dato-DXd
• Major efficacy and safety findings from the Phase III PAPILLON trial of amivantamab in combination with platinum-based chemotherapy as first-line treatment for patients with advanced NSCLC and EGFR exon 20 insertion mutations
• Other novel agents and strategies under investigation for patients with EGFR mutation-positive NSCLC, including those with EGFR exon 20 mutations

1:50 PM – 2:40 PM — Module 6: Gynecologic Cancers

Ovarian Cancer (OC); HER2-Directed Therapy for Advanced Gynecologic Cancers

• Long-term findings with olaparib, niraparib and olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed OC; factors affecting selection among these strategies
• Major efficacy and safety findings from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, olaparib and bevacizumab as maintenance therapy; clinical implications, if any
• Emerging outcomes from other Phase III research efforts, such as FIRST and KEYLYNK-001, evaluating PARP inhibitors in combination with immune checkpoint inhibitors for advanced OC
• Available efficacy and safety data from the Phase III MIRASOL trial supporting the FDA approval of mirvetuximab soravtansine for folate receptor alpha-positive, platinum-resistant OC
• Recently presented results from the Phase II PICCOLO trial evaluating mirvetuximab soravtansine for folate receptor alpha-positive, platinum-sensitive OC
• Optimal integration of mirvetuximab soravtansine into OC management algorithms
• Early research findings with the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan for heavily pretreated, platinum-resistant advanced OC; ongoing evaluation in the Phase II/III REJOICE-Ovarian01 trial
• Mechanism of action of the novel engineered cytokine nemvaleukin alfa; activity and safety observed with this agent in combination with pembrolizumab in the platinum-resistant OC cohort of the Phase I/II ARTISTRY-1 study
• Prevalence of HER2 overexpression in advanced gynecologic cancers; outcomes with T-DXd among patients with advanced HER2-positive gynecologic cancers in the DESTINY-PanTumor02 study
• FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for the management of advanced gynecologic cancers

Endometrial Cancer (EC) and Cervical Cancer (CC)

• Key efficacy and safety data with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for advanced or recurrent EC regardless of microsatellite instability (MSI)/mismatch repair (MMR) status and of durvalumab in combination with chemotherapy for MMR-deficient (dMMR) disease; optimal incorporation into up-front therapy
• Key efficacy and safety findings from the Phase III DUO-E and RUBY Part 2 trials evaluating first-line chemoimmunotherapy followed by anti-PD-1/PD-L1 antibody and PARP inhibitor maintenance for newly diagnosed advanced or recurrent EC; potential role of this strategy
• Mechanism of action of selinexor and biological rationale for its evaluation for EC, particularly TP53 wild-type disease
• Updated efficacy and safety findings with selinexor as maintenance therapy after first-line chemotherapy for TP53 wild-type advanced or recurrent EC; ongoing Phase III XPORT-EC-042 trial
• Available data, including overall survival findings, from the Phase III KEYNOTE-A18 trial evaluating the addition of pembrolizumab to chemoradiation therapy for high-risk locally advanced CC; patient selection for this strategy
• Published research with anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy with or without bevacizumab as up-front therapy for advanced CC; optimal integration into patient care

2:40 PM – 3:30 PM — Module 7: Prostate Cancer

Hormonal Therapy for Patients with Prostate Cancer

• Major efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide with leuprolide versus enzalutamide or leuprolide alone for patients with nonmetastatic hormone-sensitive prostate cancer (HSPC) and high-risk biochemical recurrence
• FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) in clinical practice
• Published data from the Phase III PRESTO trial evaluating the role of ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nonmetastatic HSPC
• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with metastatic HSPC (mHSPC)
• Key outcomes from the Phase III ARANOTE study evaluating the addition of darolutamide to ADT for patients with mHSPC; clinical implications
• Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; optimal selection of candidates for triplet therapy
• Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease; mechanism of action of capivasertib
• Emerging positive results from the Phase III CAPItello-281trial assessing capivasertib in combination with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Design, eligibility criteria and primary and secondary endpoints of the ongoing Phase III CAPItello-280 trial evaluating capivasertib in combination with docetaxel/ADT for patients with metastatic castration-resistant prostate cancer (mCRPC)

Other Available and Emerging Therapeutic Approaches

• Incidence of BRCA1/2 and other homologous recombination repair abnormalities in prostate cancer; indications for and practical implementation of genetic testing
• Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors for prostate cancer
• Key efficacy and safety findings from the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting for mCRPC; recently presented overall survival data from TALAPRO-2
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide; optimal patient selection for these approaches
• Recently presented data from the Phase III PEACE-3 trial of radium-223 and enzalutamide versus enzalutamide alone as first-line therapy for mCRPC with bone metastases; implications for clinical management
• Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC
• Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan opposite other available therapies
• Key efficacy and safety findings from the Phase III CONTACT-02 trial comparing cabozantinib/atezolizumab to a second novel hormonal therapy for patients with mCRPC and measurable soft tissue disease previously treated with a novel hormonal agent
• Other novel agents and strategies under investigation for patients with prostate cancer

3:30 PM – 3:50 PM — Afternoon Break

3:50 PM – 4:40 PM — Module 8: Biliary Tract Cancers (BTCs)

Integration of Immune Checkpoint Inhibitors into Current BTC Management

• Historical approaches to front-line treatment for advanced BTCs; impact of disease- and patient-specific factors on therapeutic selection
• Similarities and differences in the designs and patient characteristics between the Phase III TOPAZ-1 and KEYNOTE-966 studies evaluating durvalumab and pembrolizumab, respectively, in combination with chemotherapy as first-line treatment for advanced BTCs
• Published efficacy and safety findings from the TOPAZ-1 and KEYNOTE-966 studies
• FDA approvals and optimal integration of durvalumab/chemotherapy and pembrolizumab/chemotherapy into the care of patients with previously untreated advanced BTCs
• Ongoing evaluation of durvalumab in combination with alternative chemotherapy backbones in the Phase IIIb TOURMALINE study; estimated completion date
• Currently available therapies for patients without an actionable biomarker who experience disease progression on first-line therapy with chemotherapy and an anti-PD-1/PD-L1 antibody
• Other promising agents and strategies under investigation for advanced BTCs

Targeted Therapeutic Approaches for Patients with BTCs

• Spectrum and frequency of targetable molecular alterations in advanced BTCs; impact of anatomical location on incidence
• Principal findings supporting the FDA approvals of pemigatinib and futibatinib for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
• Efficacy and safety observed with T-DXd for HER2-positive BTCs, including findings from the DESTINY-PanTumor02 study; optimal incorporation of T-DXd into clinical practice
• Mechanism of action of zanidatamab and published efficacy and safety results from the pivotal Phase IIb HERIZON-BTC-01 trial investigating this agent for previously treated HER2-amplified BTCs
• Recent FDA approval of zanidatamab for previously treated unresectable or metastatic HER2-positive (IHC 3+) BTCs
• Ongoing Phase III studies, such as DESTINY-BTC01 and HERIZON-BTC-302, evaluating HER2-targeted strategies for treatment-naïve patients with HER2-overexpressing advanced BTCs

4:40 PM – 5:30 PM — Module 9: Non-Hodgkin Lymphoma (NHL)

Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies for NHL

• Major findings from Phase III studies of CAR T-cell therapy as second-line treatment for diffuse large B-cell lymphoma (DLBCL); identification of appropriate patients for this strategy
• Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and liso-cel for multiregimen-relapsed DLBCL
• Principal efficacy and safety outcomes from pivotal studies evaluating axi-cel, tis-cel and liso-cel for R/R follicular lymphoma (FL); appropriate selection of candidates and timing of application
• Published efficacy and safety results with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL); patient selection and optimal clinical use
• Key efficacy and safety outcomes from pivotal studies of bispecific antibody monotherapy with glofitamab and with epcoritamab for R/R DLBCL; evidence-based sequencing of and selection between these agents
• Available data from the Phase III STARGLO study of glofitamab in combination with gemcitabine/oxaliplatin (GemOx) versus rituximab and GemOx for patients with R/R DLBCL; clinical implications
• Available data with mosunetuzumab and epcoritamab for R/R FL; optimal incorporation opposite other available options
• Published data with and potential role of other bispecific antibodies, such as odronextamab, for R/R DLBCL and FL

Other Available and Emerging Novel Therapies for NHL

• Published results with polatuzumab vedotin in combination with chemotherapy for previously untreated DLBCL; current role of polatuzumab vedotin as a component of up-front therapy
• Long-term findings with polatuzumab vedotin in combination with BR for R/R DLBCL
• Available data with loncastuximab tesirine for R/R DLBCL; patient selection for treatment
• Key efficacy and safety findings with tafasitamab/lenalidomide for R/R DLBCL; optimal sequencing in routine practice
• Recently presented results from the Phase III inMIND trial with the addition of tafasitamab to lenalidomide/rituximab for R/R FL or marginal zone lymphoma; potential role of this strategy
• Published Phase III datasets with ibrutinib as a component of up-front therapy for older and younger patients with MCL
• Efficacy and safety outcomes from the Phase III ECHO trial with the addition of acalabrutinib to BR and rituximab maintenance for patients ≥65 years of age with previously untreated MCL; recent FDA approval
• Available research findings and ongoing studies with BTK inhibitors as monotherapy or as a component of chemotherapy-free combination regimens for MCL in the up-front and R/R settings

5:30 PM — Adjourn

Sunday, March 2, 2025  

6:45 AM – 7:45 AM — Registration and Breakfast

7:45 AM – 8:35 AM — Module 10: Colorectal Cancer (CRC)

Optimizing the Care of Patients with Nonmetastatic CRC

• Mechanistic rationale for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) monitoring in the management of CRC
• Available research findings with ctDNA-based MRD monitoring for patients with localized CRC
• Active studies examining the utility of ctDNA-based MRD testing in guiding treatment decision-making and monitoring for recurrence; potential clinical impact
• Available data with neoadjuvant immune checkpoint inhibitors for resectable nonmetastatic MSI-high (MSI-H)/dMMR CRC
• Clinical complete response rate observed with dostarlimab as an alternative to surgery for MSI-H/dMMR locally advanced rectal cancer
• Ongoing studies, such as, AZUR-1 and AZUR-2, evaluating dostarlimab in lieu of surgery or administered perioperatively for patients with resectable MSI-H/dMMR tumors
• Other ongoing trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized disease

Recent Advances in the Management of Metastatic CRC (mCRC)

• Long-term results from the Phase III KEYNOTE-177 study of front-line pembrolizumab versus chemotherapy for newly diagnosed MSI-H/dMMR mCRC
• Key efficacy and safety findings from the Phase III CheckMate 8HW trial evaluating nivolumab/ipilimumab versus chemotherapy for previously untreated MSI-H/dMMR mCRC
• Published findings from the Phase III BREAKWATER trial comparing encorafenib/cetuximab with chemotherapy to standard chemotherapy for patients with previously untreated BRAF V600E-mutant mCRC; recent FDA approval of up-front BRAF-targeted therapy
• Published data with tucatinib/trastuzumab for previously treated HER2-positive mCRC; incorporation into the treatment paradigm
• Available data with T-DXd for HER2-expressing mCRC, such as from the DESTINY-CRC01 and DESTINY-CRC02 trials
• FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for mCRC management
• Published findings with sotorasib/panitumumab and adagrasib/cetuximab for previously treated KRAS G12C-mutated mCRC
• FDA approval and current clinical role of sotorasib/panitumumab and adagrasib/cetuximab for previously treated KRAS G12C-mutated mCRC

8:35 AM – 9:25 AM — Module 11: Urothelial Bladder Cancer

Management of Nonmetastatic Urothelial Bladder Cancer

• Key findings from the KEYNOTE-057 trial assessing pembrolizumab for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who are unresponsive or refractory to BCG therapy
• Emerging positive findings from the Phase III CREST study of the subcutaneous anti-PD-1 antibody sasanlimab in combination with BCG as induction therapy with or without maintenance for patients with BCG-naïve, high-risk NMIBC
• Other ongoing Phase III trials, such as ALBAN, POTOMAC and KEYNOTE-676, investigating the combination of BCG and anti-PD-1/PD-L1 antibodies for BCG-naïve and BCG-unresponsive NMIBC
• Findings from the Phase III CheckMate 274 and AMBASSADOR/KEYNOTE-123 studies of adjuvant nivolumab and pembrolizumab, respectively, for patients with muscle-invasive bladder cancer (MIBC)
• Available findings from the Phase III NIAGARA trial evaluating durvalumab in combination with gemcitabine/cisplatin as neoadjuvant treatment followed by adjuvant durvalumab monotherapy for MIBC
• Mechanism of antitumor activity of the novel intravesical drug delivery systems TAR-200 and TAR-210
• Available findings from the Phase IIb SunRISe-1 study evaluating TAR-200 and cetrelimab, TAR-200 alone or cetrelimab alone for patients with BCG-unresponsive high-risk NMIBC who are ineligible for or decline radical cystectomy
Recent initiation of an FDA new drug application for TAR-200 for BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors; potential role of this strategy and ongoing Phase III studies of TAR-200
• Initial safety and efficacy results with the TAR-210 erdafitinib intravesical delivery system for patients with NMIBC and select FGFR alterations; ongoing evaluation in this and other settings

Optimizing the Treatment of Metastatic Urothelial Bladder Cancer (mUBC)

• Efficacy and safety results from key studies of enfortumab vedotin in combination with pembrolizumab for previously untreated mUBC, such as EV-302/KEYNOTE-A39 and cohort K of EV-103/KEYNOTE-869
• FDA approval of enfortumab vedotin/pembrolizumab as first-line therapy for mUBC regardless of cisplatin eligibility; optimal integration into practice
• Published data from the Phase III CheckMate 901 study supporting the FDA approval of nivolumab in combination with chemotherapy as first-line treatment for cisplatin-eligible patients with mUBC
• Long-term findings with and optimal integration of enfortumab vedotin for progressive mUBC
• Key data, including those from the Phase III THOR trial, with erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations; current clinical role of this approach
• Frequency of HER2 expression in mUBC; current indications for HER2 testing
• Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of T-DXd
• FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for mUBC management
• Other promising agents and strategies under investigation for mUBC

9:25 AM – 9:45 AM — Morning Break

9:45 AM – 10:35 AM — Module 12: Multiple Myeloma (MM)

Current and Emerging Therapeutic Approaches for MM

• Recently presented findings from the Phase III AQUILA study of subcutaneous daratumumab monotherapy for patients with high-risk smoldering MM; recent submission of a regulatory application to the FDA seeking approval for this strategy
• Published findings from the Phase III PERSEUS study supporting the recent FDA approval of daratumumab in combination with RVd as induction and consolidation therapy for transplant-eligible patients with newly diagnosed MM
• Key efficacy and safety findings from the Phase III IMROZ and BENEFIT trials of isatuximab in combination with RVd for transplant-ineligible patients with newly diagnosed MM; recent FDA approval of this strategy
• Recently presented findings from the Phase III CEPHEUS trial evaluating daratumumab/RVd for patients with newly diagnosed MM who are transplant ineligible or for whom transplant was not planned as initial therapy; clinical implications
• Current role of daratumumab- and isatuximab-containing front-line regimens for patients who are eligible or ineligible for transplant
• Key findings from Phase III studies exploring the role of anti-CD38 monoclonal antibodies as a component of maintenance therapy
• Long-term findings with isatuximab in combination with standard doublet regimens for R/R MM
• Published efficacy and safety data supporting the use of selinexor in combination with a proteasome inhibitor for patients with R/R MM; preliminary data with and ongoing evaluation of other selinexor-based combination strategies
• Optimal incorporation of selinexor into routine practice and practical considerations with its use
• Mechanism of action of and activity and safety observed with the cereblon E3 ligase modulators iberdomide and mezigdomide for patients with MM; ongoing evaluation and potential clinical role

CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates

• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for patients with heavily pretreated MM
• Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; recently presented overall survival findings from the CARTITUDE-4 trial
• FDA approvals of ide-cel and cilta-cel in earlier settings; optimal sequencing of CAR T-cell therapy opposite other evidence-based approaches
• Early data with and ongoing clinical research efforts evaluating CAR T-cell platforms, such as arlocabtagene autoleucel, with targets beyond BCMA
• Antitumor activity observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM; FDA approval and optimal incorporation into management algorithms
• Efficacy and safety documented with the investigational anti-BCMA bispecific antibody linvoseltamab for R/R MM; potential role
• Available efficacy and safety data supporting the FDA approval of the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of candidates for this agent
• Key efficacy and safety findings from Phase III trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone (DREAMM-7) or pomalidomide/dexamethasone (DREAMM-8) for patients with R/R MM who have received 1 or more prior lines of therapy
• Ongoing FDA review and potential role of belantamab mafodotin-based combination strategies in the management of R/R MM

10:35 AM – 11:25 AM — Module 13: Hepatocellular Carcinoma (HCC)

Current Treatment for Advanced HCC

• Long-term findings from the Phase III IMbrave150 study comparing first-line atezolizumab/bevacizumab to sorafenib for advanced unresectable HCC
• Published efficacy and safety findings, including 5-year overall survival results, from the Phase III HIMALAYA trial evaluating the combination of durvalumab/tremelimumab for previously untreated advanced HCC
• Effect of comorbidity profile, hepatic reserve and other factors on the selection between up-front atezolizumab/bevacizumab and durvalumab/tremelimumab for advanced HCC
• Clinical trial database supporting the use of sorafenib and lenvatinib as first-line therapy for unresectable HCC; selection of appropriate candidates for up-front TKI monotherapy
• Role of approved first-line multitargeted TKIs (ie, sorafenib, lenvatinib) for R/R disease
• Long-term outcomes with and current role of other approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for R/R HCC
• Key findings with anti-PD-1/PD-L1 antibody-based approaches for progressive HCC; role, if any, for patients who have experienced disease progression on first-line immunotherapeutic approaches

Promising Novel Approaches to HCC Management

• Updated efficacy and safety data with atezolizumab/bevacizumab as adjuvant treatment for localized HCC at high risk of recurrence after surgery or ablation; recent communication advising against the off-label use of this strategy
• Published efficacy and safety data from the Phase III EMERALD-1 study comparing TACE combined with durvalumab with or without bevacizumab to TACE alone for patients with unresectable HCC eligible for embolization
• Progression-free survival advantage observed in the Phase III LEAP-012 trial evaluating TACE with or without lenvatinib in combination with pembrolizumab for locoregional HCC not amenable to curative treatment
• Potential role of TACE in combination with durvalumab/bevacizumab or lenvatinib/pembrolizumab for intermediate-stage HCC
• Key data from the Phase III CheckMate 9DW study of ipilimumab/nivolumab compared to investigator’s choice of sorafenib or lenvatinib as first-line therapy for advanced HCC; potential clinical role
• Available and emerging Phase III data with other novel front-line immunotherapeutic strategies, such as camrelizumab/rivoceranib, toripalimab/bevacizumab and tislelizumab, in advanced HCC

11:25 AM – 12:15 PM — Module 14: Systemic Mastocytosis and Myelofibrosis

Systemic Mastocytosis (SM)

• Features of various SM subtypes; impact of disease subtype on prognosis and treatment
• Rationale for targeting the KIT D816V mutation in patients with SM; mechanistic similarities and differences between approved (avapritinib) and next-generation (eg, elenestinib, bezuclastinib) KIT D816V inhibitors
• Published efficacy and safety findings from the pivotal Phase II PIONEER trial of avapritinib versus placebo for patients with indolent SM whose symptoms were not adequately controlled with standard therapy
• Outcomes achieved in key studies, such as EXPLORER and PATHFINDER, evaluating avapritinib for advanced SM
• Appropriate selection of patients with various SM subtypes for treatment with avapritinib
• Available safety and efficacy data from Part 1 of the HARBOR trial of elenestinib for patients with indolent SM whose symptoms are not adequately controlled by best supportive care; ongoing evaluation of elenestinib for patients with indolent and advanced SM, respectively, in HARBOR Part 2 and the AZURE study
• Early results with and ongoing investigation of bezuclastinib for nonadvanced and advanced SM

Myelofibrosis (MF)

• Published research database supporting the use of ruxolitinib for patients with intermediate- and high-risk MF; impact of ruxolitinib on symptom control and survival
• Key efficacy and safety findings with fedratinib for patients with newly diagnosed MF and those resistant or intolerant to ruxolitinib; selection of candidates for treatment with fedratinib
• Incidence of thrombocytopenia and anemia in patients with newly diagnosed MF and in those with prior JAK inhibitor exposure
• Published clinical research findings with pacritinib for MF, including among patients with baseline thrombocytopenia
• FDA approval of pacritinib for patients with MF and severe thrombocytopenia; optimal use in clinical practice
• Key findings from the Phase III MOMENTUM study of momelotinib versus danazol for symptomatic, anemic patients who previously received a JAK inhibitor
• Efficacy and safety of momelotinib compared to ruxolitinib in the subset of JAK inhibitor-naïve patients with severe anemia in the Phase III SIMPLIFY-1 trial
• FDA approval of momelotinib for patients with MF and disease-related anemia; current role in disease management
• Retrospective analysis of the PERSIST-2 study to evaluate the utility of pacritinib for patients with MF and severe anemia; role, if any, of pacritinib in this setting
• Promising agents and strategies under investigation for MF

12:15 PM – 1:00 PM — Lunch Break

1:00 PM – 1:50 PM — Module 15: Immunotherapy and Other Nontargeted Approaches for NSCLC

Management of NSCLC without a Targetable Mutation

• Principal findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for patients with resectable Stage IB to IIIA NSCLC
• Published data from the Phase III AEGEAN, KEYNOTE-671 and CheckMate 77T trials assessing durvalumab, pembrolizumab and nivolumab, respectively, in combination with chemotherapy as neoadjuvant therapy and continued as a single agent after surgery for resectable NSCLC
• Key findings from the IMpower010 and PEARLS/KEYNOTE-091 studies of atezolizumab and pembrolizumab, respectively, as adjuvant treatment after surgical resection and platinum-based chemotherapy
• Selection of appropriate candidates with localized NSCLC for neoadjuvant versus perioperative versus adjuvant anti-PD-1/PD-L1 antibody therapy
• Long-term findings observed with consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
• Patient selection for and practical implementation of consolidation durvalumab for locally advanced NSCLC
• Mechanisms of antitumor activity of oleclumab and monalizumab; available data and ongoing research combining these agents with durvalumab consolidation in locally advanced NSCLC

First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation

• Major findings from clinical trials evaluating anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy as first-line treatment for metastatic NSCLC
• Long-term follow-up from Phase III trials evaluating anti-PD-1/PD-L1 and anti-CTLA-4 combinations with and without chemotherapy for previously untreated metastatic NSCLC
• Incidence of HER2 overexpression in patients with NSCLC; implications for biomarker assessment
• Published data establishing the efficacy of T-DXd for HER2-overexpressing NSCLC, including findings from DESTINY-Lung03; current clinical role
• Prevalence of c-Met overexpression in NSCLC; structural components and mechanism of antitumor activity of telisotuzumab vedotin
• Available efficacy and safety findings from the Phase II LUMINOSITY trial evaluating telisotuzumab vedotin for previously treated c-Met-overexpressing NSCLC; ongoing Phase III TeliMET NSCLC-01 study
• Key data from Phase III studies, such as LUNAR and METIS, evaluating tumor treating fields (TTFields) as a component of treatment for patients with advanced NSCLC
• Other novel agents and strategies under investigation for patients with metastatic NSCLC without a targetable tumor mutation

1:50 PM – 2:40 PM — Module 16: Pancreatic Cancer

Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD)

• Effect of patient age, comorbidities and prior (neo)adjuvant therapy, if any, on the choice of first-line treatment for metastatic PAD
• Historic datasets establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
• Design, eligibility criteria and primary and secondary endpoints of the Phase III NAPOLI-3 trial evaluating front-line treatment with nanoliposomal irinotecan (nal-IRI) in combination with 5-FU/leucovorin (LV) and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for advanced PAD
• Key efficacy findings, including updated overall survival data, with NALIRIFOX from the NAPOLI-3 study
• Recent FDA approval of NALIRIFOX as first-line therapy for metastatic PAD; selection of candidates for this regimen
• Comparative tolerability/toxicity profile of NALIRIFOX versus other available chemotherapeutic strategies for patients with newly diagnosed metastatic PAD; optimal management of toxicities
• Long-term efficacy and safety outcomes documented with nal-IRI in combination with 5-FU/LV for patients with metastatic PAD progressing on gemcitabine-based therapy; current clinical role of nal-IRI in this setting

Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches

• Incidence of BRCA1/2 mutations and other DNA damage repair abnormalities in patients with PAD; guideline-endorsed algorithms for genetic testing
• Long-term findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD and a germline BRCA mutation
• Incidence of neuregulin 1 (NRG1) gene fusions in patients with advanced PAD; rationale for targeting NRG1 fusions with zenocutuzumab
• Efficacy and safety of zenocutuzumab among patients with metastatic PAD and NRG1 fusions in the pivotal Phase I/II eNRGy study
• Recent FDA approval and optimal incorporation of zenocutuzumab for previously treated advanced PAD harboring NRG1 gene fusions
• Mechanism of antitumor activity of TTFields, rationale for their investigation in PAD and early clinical trial data
• Emerging overall survival advantage documented with the addition of TTFields to gemcitabine/nab paclitaxel for unresectable locally advanced PAD in the Phase III PANOVA-3 trial
• Potential clinical role of TTFields for patients with unresectable locally advanced PAD
• Other promising investigational treatment strategies for patients with PAD

2:40 PM – 3:30 PM — Module 17: Gastroesophageal Cancer

Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers

• Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable MSI-H/dMMR gastric/gastroesophageal junction (GEJ) adenocarcinoma
• Design, eligibility criteria and primary and secondary endpoints of the Phase III MATTERHORN study of neoadjuvant durvalumab and fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) chemotherapy followed by adjuvant durvalumab for patients with resectable gastric/GEJ cancer
• Improvement in pathologic complete response rate with the addition of durvalumab to neoadjuvant FLOT in the MATTERHORN study; ongoing evaluation of perioperative durvalumab and potential clinical role of this strategy
• Key efficacy and safety outcomes with adjuvant nivolumab for patients with esophageal/GEJ cancer after neoadjuvant chemoradiation therapy and surgery; clinical role
• Clinical and biological factors, such as location of the primary tumor, histology, PD-L1 expression, MSI/MMR status and CLDN18.2 expression, affecting the choice of up-front therapy for patients with metastatic HER2-negative gastroesophageal cancers
• Published datasets demonstrating the efficacy and safety of first-line nivolumab-, pembrolizumab- and tislelizumab-containing regimens for advanced gastric, GEJ and esophageal cancer; impact of PD-L1 expression on outcomes
• Recent FDA ODAC meeting recommending PD-L1 thresholds for the use of immune checkpoint inhibitors for previously untreated HER2-negative gastroesophageal cancers

Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers

• Incidence and clinical relevance of CLDN18.2 expression in gastric/GEJ cancer; appropriate methods to assess CLDN18.2 status
• Key efficacy and safety results of the Phase III SPOTLIGHT and GLOW trials evaluating zolbetuximab in combination with chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
• Recent FDA approval and clinical role of up-front zolbetuximab/chemotherapy
• Early efficacy and safety results with CLDN18.2-targeted antibody-drug conjugates, such as AZD0901 and EO-3021, under evaluation for advanced gastroesophageal cancers
• Optimal approach to first-line therapy for patients with HER2-positive gastric/GEJ cancer; FDA approval of pembrolizumab/chemotherapy/trastuzumab for previously untreated HER2-positive, PD-L1-positive gastric/GEJ adenocarcinoma
• Efficacy and safety findings from the DESTINY-Gastric01 and DESTINY-Gastric02 studies evaluating T-DXd for patients with progressive HER2-positive gastric/GEJ cancer
• Optimal integration of T-DXd into the management paradigm for advanced HER2-positive gastroesophageal tumors
• Other promising targeted agents and strategies under investigation for advanced gastroesophageal cancers

3:30 PM — Meeting Adjourns